drugset / Trial / NCT03938389
The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans
Phase 4
Active not recruiting
90 enrolled
Ohio State University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
The primary objective is to examine the impact of the Renin-Angiotensin-Aldosterone System (RAAS) blockade with medications (valsartan) or RAAS and neprilysin inhibition (valsartan/sacubitril) vs. placebo on changes in blood sugar and insulin secretion from the pancreas over 26 weeks assessed with glucose clamp studies among African Americans (AAs) with impaired glucose tolerance. The investigators hypothesize that combined RAAS/neprilysin inhibition will lead to greater improvement in insulin release from the pancreas and improved blood sugar compared to RAAS inhibition alone among AAs with impaired glucose tolerance.
Timeline
- Start
- 2020-02-25
- Primary completion
- 2024-02-08
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sacubitril-Valsartan | Unknown | — | — |
| Comparator | Valsartan | Small molecule | 160 mg | — |